Verastem, Inc VSTM Stock Price Today, Quote & News

This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.52% per year. These returns cover a period from January 1, 1988 through February 6, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. 5 brokers have issued 1-year price objectives for Verastem’s stock. Their VSTM share price forecasts range from $3.00 to $6.00. On average, they predict the company’s share price to reach $4.25 in the next twelve months.

The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. Join thousands of traders who make more informed decisions with our premium features.

My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market’s returns over the past century! I think it’s a crying shame folks goldwell united states of america don’t know how powerful dividends are. Verastem has a short interest ratio (“days to cover”) of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

News and Social Media Coverage

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Verastem stock was originally listed at a price of $11.09 in Jan 27, 2012.

Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services.

RATIOS/PROFITABILITY

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. An affiliate of Public may be “testing the waters” and considering making an offering of securities under Tier 2 of Regulation A. No money or other consideration is being solicited and, if sent in response, will not be accepted. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. An indication of interest to purchase securities involves no obligation or commitment of any kind.

Real-time quotes, advanced visualizations, backtesting, and much more. All values as of most recently reported quarter unless otherwise noted. There is no website visitor data available for this stock. By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verastem started at buy with $6 stock price target at Truist

During the last day, the stock moved $0.0395 between high and low, or 9.39%. For the last week the stock has had daily average volatility of 12.28%. Verastem exhibits a price/sales ratio which is less than the industry average for drugs stocks listed on the NASDAQ. Verastem exhibits a price/book ratio which is within a 15% range of the industry average for drugs stocks listed on the NASDAQ.

According to the current price, Verastem is 21.04% away from the 52-week high. The 8 analysts offering price forecasts for Verastem have a median target of 4.50, with a high estimate of 8.00 and a low estimate of 3.00. The median estimate represents a 9.93 difference from the last price of 0.45. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, https://day-trading.info/ randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination wi… The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods.

Earnings and Valuation

Real-time analyst ratings, insider transactions, earnings data, and more. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

The company’s pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase inhibition. Verastem stock has received a consensus rating of buy. The average rating score is and is based on 8 buy ratings, 0 hold ratings, and 0 sell ratings. The low in the last 52 weeks of Verastem stock was 0.29. According to the current price, Verastem is 154.40% away from the 52-week low. The high in the last 52 weeks of Verastem stock was 2.13.

VSTM Earnings

All other current web features including annual reports, price sensitive announcements, dividends and earnings transcripts are free to use here on our web app. JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. None of these entities provide legal, tax, or accounting advice. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.

Other market data may be delayed by 15 minutes or more. Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months. Verastem’s dividend yield of 0.0% is less than the industry average for drugs stocks listed on the NASDAQ. We are working on updating this web app to fully enable Quantitative Ratios.

Wainwright maintained a Buy rating on Verastem (VSTM – Research Report), with a price target of $3.00. The company’s shares closed last Friday at $0.39.Lee CFA covers the … This stock may move very much during the day and with periodic low trading volume this stock is considered to be “very high risk”.

Intraday data delayed at least 15 minutes or per exchange requirements. StockInvest.us is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon StockInvest.us. By using the site you agree and are held liable for your own investment decisions and agree to the Terms of Use and Privacy Policy.Please read the full disclaimer here. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence .

What analysts recommend for VSTM stock, on a scale from 1 to 5. Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile. One share of VSTM stock can currently be purchased for approximately $0.43. Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat’s FREE daily newsletter. The P/E ratio of Verastem is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. 60.59% of the stock of Verastem is held by institutions.

• Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”).
• The company’s stock opened at $11 a share on the Nasdaq, up from its initial public offering price of $10…
• JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries.
• Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer.
• Sign up for a Robinhood brokerage account to buy or sell Verastem stock and options commission-free.

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma /mitogen-activated protein kinase clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen’s KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts. Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. The indication in FL is approved under accelerated approval based on overall response rate.